for people ages 18 years and up (full criteria)
at Los Angeles, California and other locations
study started
estimated completion
Principal Investigator
by Zev Wainberg



This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Official Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies


Advanced Solid Tumor, NSCLC, Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, DLBCL, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Non-Hodgkin Lymphoma, Zimberelimab


You can join if…

Open to people ages 18 years and up

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Adequate organ and marrow function

You CAN'T join if...

  • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
  • Prior treatment with an anti-TIGIT antibody.
  • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
  • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
  • Discontinued prior immunotherapy for immune related adverse events with a high severity.

    NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


  • University of California, Los Angeles
    Los Angeles California 90095 United States
  • Mayo Clinic Arizona - Mayo Clinic Hospital
    Phoenix Arizona 85054-4502 United States

Lead Scientist at UCLA

  • Zev Wainberg
    HS Clinical Professor, Medicine. Authored (or co-authored) 138 research publications


in progress, not accepting new patients
Start Date
Completion Date
Arcus Biosciences, Inc.
Phase 1 research study
Study Type
About 94 people participating
Last Updated